{"organizations": [], "uuid": "ab38e6b2b0e4a115cbbbbb785589c6de43623f5d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-opiant-pharma-announces-positive-d/brief-opiant-pharma-announces-positive-data-from-a-phase-i-clinical-study-of-opnt003-idUSFWN1Q20UJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T15:19:00.000+02:00", "replies_count": 0, "uuid": "ab38e6b2b0e4a115cbbbbb785589c6de43623f5d"}, "author": "", "url": "https://www.reuters.com/article/brief-opiant-pharma-announces-positive-d/brief-opiant-pharma-announces-positive-data-from-a-phase-i-clinical-study-of-opnt003-idUSFWN1Q20UJ", "ord_in_thread": 0, "title": "BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "opiant pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 21 PM / in 13 minutes BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003 Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Opiant Pharmaceuticals Inc: \n* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003 \n* OPIANT PHARMACEUTICALS INC - ANTICIPATES TO SUBMIT A NEW DRUG APPLICATION FOR DRUG AND INTRANASAL DELIVERY DEVICE COMBINATION IN 2020 \n* OPIANT PHARMACEUTICALS INC - ANTICIPATE SUBMITTING AN NDA FOR OPNT003 IN 2020 \n* OPIANT - HAS FULL COMMERCIAL RIGHTS TO OPNT003; SUBMITTED GRANT APPLICATION TO NATIONAL INSTITUTES OF HEALTH TO FUND DEVELOPMENT TO NDA READY STAGE Source text for Eikon:  ", "external_links": [], "published": "2018-02-12T15:19:00.000+02:00", "crawled": "2018-02-12T15:48:13.000+02:00", "highlightTitle": ""}